Junshi Biosciences and Coherus BioSciences Announce Initiation of Rolling Submission of BLA for Toripalimab to the U.S. FDA for the Treatment of Nasopharyngeal Carcinoma
03 mars 2021 06h45 HE
|
Junshi Biosciences
- BLA submitted with FDA’s breakthrough therapy designation – SHANGHAI, China and REDWOOD CITY, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd....
Junshi Biosciences and AstraZeneca Announce Strategic Collaboration to Commercialize Toripalimab in China
28 févr. 2021 20h15 HE
|
Junshi Biosciences
-- Junshi grants AstraZeneca exclusive promotion rights of toripalimab in mainland China for the urothelial carcinoma indications and for all indications in non-core areas-- Junshi will continue to be...
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
26 févr. 2021 12h35 HE
|
Junshi Biosciences
SHANGHAI, China, Feb. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
NMPA Approves Toripalimab in Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma after Failure of at Least Two Lines of Prior Systemic Therapy
21 févr. 2021 18h00 HE
|
Junshi Biosciences
-- 1st approval of any checkpoint inhibitor in nasopharyngeal carcinoma in the world -- 2nd indication approved for Toripalimab in China SHANGHAI, China, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Junshi...
Junshi Biosciences Announces Acceptance by the NMPA of Supplemental New Drug Application for Toripalimab Combined with Chemotherapy for The First-Line Treatment of Nasopharyngeal Carcinoma
18 févr. 2021 21h18 HE
|
Junshi Biosciences
SHANGHAI, China, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
10 févr. 2021 02h45 HE
|
Junshi Biosciences
Etesevimab and bamlanivimab administered together is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19More than...
Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada
01 févr. 2021 07h53 HE
|
Junshi Biosciences
Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option...
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
26 janv. 2021 10h35 HE
|
Junshi Biosciences
Trial met primary endpoint and key secondary endpoints with high statistical significanceResults from more than 1,000 high-risk patients were consistent with previous dataIn November, Lilly submitted...
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
24 janv. 2021 19h07 HE
|
Junshi Biosciences
SHANGHAI, China, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...
Junshi Biosciences Announces Inclusion of Toripalimab in The China National Reimbursement Drug List
28 déc. 2020 20h22 HE
|
Junshi Biosciences
SHANGHAI, China, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and...